Hal Barron - Articles and news items

Roche logo

Roche and Chugai’s new subcutaneous formulation of RoActemra® (tocilizumab) gains CHMP positive opinion in Europe for moderate to severe rheumatoid arthritis

Industry news / 20 December 2013 / Roche

“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment…”

Roche logo

Roche’s Kadcyla approved in the EU for advanced HER2-positive breast cancer

Industry news / 20 November 2013 / Roche

Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer…

Roche logo

Data show Roche’s new subcutaneous form of Herceptin is preferred by patients and could save resources in Europe’s hospitals

Industry news / 30 September 2013 / Roche

Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients…

Roche logo

Roche’s Kadcyla helped people with advanced HER2-positive breast cancer live longer without their disease worsening in new phase III study

Industry news / 28 September 2013 / Roche

Kadcyla nearly doubled the time that patients lived without their disease worsening compared with treatment of physician’s choice…

Roche logo

Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer

Industry news, News / 2 September 2013 / Roche

Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission…

Roche logo
Roche logo

Roche’s Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma

Industry news, News / 15 July 2013 / Roche

The European Commission has granted conditional approval to Erivedge…

Roche logo

Roche halts investigation of aleglitazar following regular safety review of phase III trial

Industry news, News / 10 July 2013 / Roche

“The safety of patients is our first priority…”

Roche logo

FDA grants Roche’s obinutuzumab (GA101) Priority Review for previously untreated chronic lymphocytic leukemia

Industry news, News / 3 July 2013 / Roche

FDA decision on the GA101 BLA is expected by the end of 2013…

Roche logo

FDA grants Roche’s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer

Industry news, News / 2 July 2013 / Roche

The U.S. FDA has accepted the company’s sBLA for the use of a Perjeta®…

Roche logo

CHMP recommends EU approval of Roche’s Subcutaneous Herceptin for HER2 positive breast cancer

Industry news, News / 28 June 2013 / Roche

“Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer…”

Roche logo

Roche’s Avastin approved in Japan for treatment of the most aggressive form of brain cancer

Industry news, News / 17 June 2013 / Roche

First approval of Avastin for the treatment of newly diagnosed glioblastoma…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...